21.50
-0.02 (-0.09%)
| Penutupan Terdahulu | 21.52 |
| Buka | 21.49 |
| Jumlah Dagangan | 1,027,410 |
| Purata Dagangan (3B) | 2,948,252 |
| Modal Pasaran | 2,110,034,432 |
| Harga / Pendapatan (P/E Ke hadapan) | 16.86 |
| Harga / Jualan (P/S) | 8.62 |
| Harga / Buku (P/B) | 21.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -13.58% |
| Margin Operasi (TTM) | -5.72% |
| EPS Cair (TTM) | -0.260 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 93.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 54.52% |
| Nisbah Semasa (MRQ) | 2.73 |
| Aliran Tunai Operasi (OCF TTM) | -25.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.61 M |
| Pulangan Atas Aset (ROA TTM) | -7.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Avadel Pharmaceuticals plc | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 1.0 |
| Purata | -0.67 |
|
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.83% |
| % Dimiliki oleh Institusi | 83.14% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |